Please login to the form below

Not currently logged in
Email:
Password:

rFIXFc

This page shows the latest rFIXFc news and features for those working in and with pharma, biotech and healthcare.

FDA starts review of Biogen Idec's haemophilia A therapy

FDA starts review of Biogen Idec's haemophilia A therapy

Eloctate was developed in partnership with Swedish Orphan Biovitrum (Sobi), which also collaborated on the development of Biogen Idec's haemophilia B candidate Alprolix (recombinant factor IX Fc fusion protein; rFIXFc).

Latest news

  • Biogen submits haemophilia drug for US approval Biogen submits haemophilia drug for US approval

    Backing the submission of rFIXFc are results from B-LONG, which Biogen says is the largest phase III clinical study in haemophilia B to date. ... This study demonstrated that rFIXFc was both clinically effective and safe, helping to prevent bleeding

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics